Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT

• DOI: 10.1038/s41375-021-01276-4
• Publication Date: 2021-05-22T16:02:28Z
• Authors: Nicolaus Kröger; Giulia Sbianchi; Tiarlan Sirait; Christine Wolschke; Dietrich Beelen; Jakob Passweg; Marie Robin; Radovan Vrhovac; Grzegorz Helbig; Katja Sockel; Eibhlin Conneally; Marie Thérèse Rubio; Yves Beguin; Jürgen Finke; Paolo Bernasconi; Elena Morozova; Johannes Clausen; Peter von dem Borne; Nicolaas Schaap; Wilfried Schroyens; Francesca Patriarca; Nicola Di Renzo; Zeynep Arzu Yeğin; Patrick Hayden; Donal McLornan; Ibrahim Yakoub-Agha
• Keywords: Ruxolitinib

Abstract JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the impact of pretreatment RUX on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) remains to be determined. We evaluated 551 who received HSCT without ( n = 274) or 277) pretreatment. The overall leukocyte engraftment day 45 was 92% and significantly higher responsive than those had no lost response (94% vs. 85%, p 0.05). 1-year non-relapse mortality 22% significant difference between arms. In a multivariate analysis (MVA) pretreated ongoing spleen at transplant lower risk relapse (8.1% 19.1%; 0.04)] better 2-year event-free survival (68.9% 53.7%; 0.02) comparison For only factors were age > 58 years 0.03) HLA mismatch donor 0.001). prior did not negatively time best outcome.